Several other research firms have also recently issued reports on ATRC. Needham & Company LLC reiterated a buy rating and set a $23.00 price objective (down previously from $25.00) on shares of AtriCure in a research report on Tuesday, January 16th. Canaccord Genuity lifted their price objective on shares of AtriCure from $24.00 to $26.00 and gave the company a buy rating in a research report on Tuesday, February 27th. BidaskClub upgraded shares of AtriCure from a sell rating to a hold rating in a research report on Friday, February 23rd. ValuEngine upgraded shares of AtriCure from a sell rating to a hold rating in a research report on Wednesday, March 7th. Finally, Piper Jaffray Companies restated a buy rating and issued a $24.00 price target on shares of AtriCure in a research report on Sunday, December 10th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $24.67.
Shares of AtriCure stock opened at $19.83 on Friday. The stock has a market cap of $726.80, a P/E ratio of -23.89 and a beta of 0.30. The company has a current ratio of 2.58, a quick ratio of 1.87 and a debt-to-equity ratio of 0.23. AtriCure has a 1 year low of $14.88 and a 1 year high of $25.18.
In other AtriCure news, Director Elizabeth D. Krell sold 10,000 shares of AtriCure stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $20.00, for a total transaction of $200,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Justin J. Noznesky sold 4,000 shares of AtriCure stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $17.03, for a total transaction of $68,120.00. The disclosure for this sale can be found here. Insiders own 11.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of ATRC. BlackRock Inc. boosted its stake in AtriCure by 22.1% during the fourth quarter. BlackRock Inc. now owns 2,731,558 shares of the medical device company’s stock worth $49,823,000 after buying an additional 494,306 shares during the period. Citadel Advisors LLC boosted its stake in AtriCure by 1,193.9% during the third quarter. Citadel Advisors LLC now owns 334,565 shares of the medical device company’s stock worth $7,484,000 after buying an additional 308,708 shares during the period. Cortina Asset Management LLC boosted its stake in AtriCure by 101.4% during the third quarter. Cortina Asset Management LLC now owns 440,072 shares of the medical device company’s stock worth $9,844,000 after buying an additional 221,605 shares during the period. Peregrine Capital Management LLC boosted its stake in AtriCure by 22.7% during the fourth quarter. Peregrine Capital Management LLC now owns 1,134,406 shares of the medical device company’s stock worth $20,692,000 after buying an additional 209,666 shares during the period. Finally, Neuberger Berman Group LLC boosted its stake in shares of AtriCure by 9.2% during the third quarter. Neuberger Berman Group LLC now owns 900,296 shares of the medical device company’s stock valued at $20,140,000 after purchasing an additional 75,827 shares during the period. 87.50% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This piece was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://stocknewstimes.com/2018/03/20/atricure-atrc-raised-to-c-at-thestreet.html.
AtriCure Company Profile
AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.